Progenics Presents Novel Multiplex PI3-Kinase Inhibitors At American Association For Cancer Research Conference On Protein Translation And Cancer

February 08th, 2010 | Category: Cancer

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways

involved in the growth and survival of cancer cells. The compounds were identified as part of the Company’s ongoing oncology drug discovery efforts…

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • Reddit
  • StumbleUpon
  • Technorati
Related Articles
No related posts

No comments yet. Be the first.

Leave a reply